2325 Stock Overview
Operates as a medical operation service provider in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2325 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Yunkang Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.54 |
| 52 Week High | HK$12.30 |
| 52 Week Low | HK$6.00 |
| Beta | -0.31 |
| 1 Month Change | 7.71% |
| 3 Month Change | -8.72% |
| 1 Year Change | -34.43% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.29% |
Recent News & Updates
Is Yunkang Group (HKG:2325) Using Debt In A Risky Way?
Dec 03
Yunkang Group Limited's (HKG:2325) Shareholders Might Be Looking For Exit
Jul 05Recent updates
Is Yunkang Group (HKG:2325) Using Debt In A Risky Way?
Dec 03Yunkang Group Limited's (HKG:2325) Shareholders Might Be Looking For Exit
Jul 05Some Yunkang Group Limited (HKG:2325) Analysts Just Made A Major Cut To Next Year's Estimates
Apr 04Estimating The Intrinsic Value Of Yunkang Group Limited (HKG:2325)
Sep 06Why We're Not Concerned About Yunkang Group Limited's (HKG:2325) Share Price
Jul 22We Think You Should Be Aware Of Some Concerning Factors In Yunkang Group's (HKG:2325) Earnings
Sep 29Yunkang Group Limited (HKG:2325) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 19Shareholder Returns
| 2325 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 9.3% | -1.3% | -0.5% |
| 1Y | -34.4% | -17.8% | 19.9% |
Return vs Industry: 2325 underperformed the Hong Kong Healthcare industry which returned -17.8% over the past year.
Return vs Market: 2325 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 2325 volatility | |
|---|---|
| 2325 Average Weekly Movement | 8.9% |
| Healthcare Industry Average Movement | 8.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2325 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2325's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,459 | Yong Zhang | www.yunkanghealth.com |
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests.
Yunkang Group Limited Fundamentals Summary
| 2325 fundamental statistics | |
|---|---|
| Market cap | HK$4.51b |
| Earnings (TTM) | -HK$295.32m |
| Revenue (TTM) | HK$846.80m |
5.3x
P/S Ratio-15.3x
P/E RatioIs 2325 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2325 income statement (TTM) | |
|---|---|
| Revenue | CN¥794.58m |
| Cost of Revenue | CN¥522.26m |
| Gross Profit | CN¥272.32m |
| Other Expenses | CN¥549.42m |
| Earnings | -CN¥277.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 34.27% |
| Net Profit Margin | -34.87% |
| Debt/Equity Ratio | 59.7% |
How did 2325 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield-4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yunkang Group Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zeyu Hu | SPDB International Holdings Limited |
| Zhengning Ding | SPDB International Holdings Limited |